Repligen to Acquire Refine Technology for $24.5M

Repligen, a Waltham, Mass., biotech firm that’s seen fast growth since deciding to focus on products used to make biologic drugs, has acquired a 17-employee New Jersey company for cash and stock worth $24.5 million. The company announced that it will pay $20.5 million in cash plus 215,000 shares of stock to Refine Technology, a company that makes a device to significantly increase the product yield during the fermentation step of the biologic drug manufacturing process. Read the full story